Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 1
2012 2
2013 4
2014 5
2017 3
2018 1
2019 4
2020 5
2021 4
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein.
Albornoz EA, Amarilla AA, Modhiran N, Parker S, Li XX, Wijesundara DK, Aguado J, Zamora AP, McMillan CLD, Liang B, Peng NYG, Sng JDJ, Saima FT, Fung JN, Lee JD, Paramitha D, Parry R, Avumegah MS, Isaacs A, Lo MW, Miranda-Chacon Z, Bradshaw D, Salinas-Rebolledo C, Rajapakse NW, Wolvetang EJ, Munro TP, Rojas-Fernandez A, Young PR, Stacey KJ, Khromykh AA, Chappell KJ, Watterson D, Woodruff TM. Albornoz EA, et al. Among authors: wijesundara dk. Mol Psychiatry. 2023 Jul;28(7):2878-2893. doi: 10.1038/s41380-022-01831-0. Epub 2022 Nov 1. Mol Psychiatry. 2023. PMID: 36316366 Free PMC article.
IL-4 and IL-13 receptors: Roles in immunity and powerful vaccine adjuvants.
Ranasinghe C, Trivedi S, Wijesundara DK, Jackson RJ. Ranasinghe C, et al. Among authors: wijesundara dk. Cytokine Growth Factor Rev. 2014 Aug;25(4):437-42. doi: 10.1016/j.cytogfr.2014.07.010. Epub 2014 Jul 23. Cytokine Growth Factor Rev. 2014. PMID: 25159217 Review.
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial.
Chappell KJ, Mordant FL, Amarilla AA, Modhiran N, Liang B, Li Z, Wijesundara DK, Lackenby JA, Griffin P, Bennet JK, Hensen L, Zhang W, Nguyen THO, Tran MH, Tapley P, Barnes J, Reading PC, Kedzierska K, Ranasinghe C, Subbarao K, Watterson D, Young PR, Munro TP. Chappell KJ, et al. Among authors: wijesundara dk. EBioMedicine. 2023 Nov;97:104842. doi: 10.1016/j.ebiom.2023.104842. Epub 2023 Oct 20. EBioMedicine. 2023. PMID: 37865043 Free PMC article. Clinical Trial.
34 results